Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...
Crain's New York Business14d
Midtown company tells investors esophageal pre-cancer screening should be an easier pill to swallow
A Midtown-based diagnostics company raised capital in a deal to advance its novel approach to screening for the risk factors of esophageal cancer, a highly deadly cancer for which a diagnosis is ...
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...
BTIG Keeps Their Buy Rating on Lucid Diagnostics (LUCD)
In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Lucid Diagnostics (LUCD – Research Report), with a price ...
CWRU, UH researchers test noninvasive esophageal cancer screening technology
A multi-site study, backed by an $8 million NIH grant, will evaluate the effectiveness of Lucid Diagnostics' EsoCheck and ...
Lucid Diagnostics stock dips on $15.3M share offering
Shares of Lucid Diagnostics (NASDAQ:LUCD) fell over 14% premarket on Tuesday after the company launched a stock offering to raise approximately $15.3M in gross proceeds. The diagnostics company has ...
Lucid Diagnostics secures first positive insurance coverage for EsoGuard test
Lucid Diagnostics (LUCD) announced that Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, ...
Nasdaq23d
Lucid Diagnostics Restores Nasdaq Listing Compliance
(RTTNews) - Lucid Diagnostics Inc. (LUCD), a US-based commercial-stage cancer prevention diagnostics company and a subsidiary of PAVmed Inc., has regained compliance with the Nasdaq Capital Market ...
Medindia2d
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics Inc.�(Nasdaq: LUCD)�("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, a ...
Morningstar3d
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy The ENVET-BE study reviewed real-world data from a ...
Finanznachrichten3d
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions ...